Neonc Technologies Holdings Business Update
NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.